No Data
No Data
Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed for Stoke Therapeutics Amid Solid Q2 Performance and Regulatory Progress
Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham
Stoke Therapeutics | 10-Q: Q2 2024 Earnings Report
Promising Outlook for Stoke Therapeutics' Zorevunersen as a Disease-Modifying Therapy in Dravet Syndrome
Buy Rating Reaffirmed for Stoke Therapeutics Amidst Clinical Progress and Strong Financial Footing